CT327 Phase IIb Atopic Dermatitis Study

• Research type

  Research Study

• Full title

  A phase II randomised, double blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of CT327 topical ointment (0.05% and 0.5% w/w) compared to vehicle, in subjects with mild or moderate atopic dermatitis with at least moderate pruritus

• IRAS ID

  127257

• Contact name

  Hakim

• Sponsor organisation

  Creabilis Limited

• Eudract number

  2012-005389-36

• Clinicaltrials.gov Identifier

  NCT01808157

• REC name

  London - Central Research Ethics Committee

• REC reference

  13/LO/0485

• Date of REC Opinion

  22 May 2013

• REC opinion

  Further Information Favourable Opinion